Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

Terry McCormack, Peter Harvey, Richard Gaunt, Victoria Allgar, Robert Chipperfield, Paul Robinson

To cite this version:


HAL Id: hal-00552661

https://hal.archives-ouvertes.fr/hal-00552661

Submitted on 6 Jan 2011
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

**Journal:** International Journal of Clinical Practice

**Manuscript ID:** IJCP-01-10-0046.FX5.R1

**Manuscript Type:** EXPEDITED Clinical Trial - $1500

**Date Submitted by the Author:** 23-Mar-2010

**Complete List of Authors:** McCormack, Terry; Whitby Group Practice
Harvey, Peter; The Crouch Oak Family Practice
Gaunt, Richard; Rowden Medical Practice
Allgar, Victoria; Hull York Medical School
Chipperfield, Robert; Schering-Plough, Medical
Robinson, Paul; Merck Sharp & Dohme Ltd

**Specialty area:**
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

Authors

Terry McCormack,¹ Peter Harvey,² Richard Gaunt,³ Victoria Allgar,⁴ Robert Chipperfield,⁵ Paul Robinson⁶

Affiliations

¹General Practitioner, Whitby Group Practice, Spring Vale Medical Centre, Whitby YO21 1SD
²General Practitioner, The Crouch Oak Family Practice, 45 Station Road, Addlestone KT15 2BH
³General Practitioner, Rowden Medical Practice, Rowden Hill, Chippenham SN15 2SB
⁴Senior Lecturer in Medical Statistics, Hull York Medical School, University of York, York YO10 5DD
⁵Strategic Healthcare Development Manager, Schering-Plough Ltd, Welwyn Garden City AL7 1TW
⁶Medical Director, Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon EN11 9BU

Corresponding author:

Terry McCormack, Whitby Group Practice, Spring Vale Medical Centre, Whitby YO21 1SD
Disclosures

TM has received research grants, educational grants and advisory board honoraria from AstraZeneca, Merck Sharp & Dohme and Schering-Plough, and received expenses from Pfizer to give a lecture. PH has received research grants and consultancy or speaking honoraria from AstraZeneca, Merck Sharp & Dohme, Pfizer and Schering-Plough. RG has received advisory board honoraria from Merck Sharp & Dohme. RC is an employee of Schering-Plough. PR is an employee of Merck Sharp & Dohme. VA has no potential conflicts of interest to declare.
ABSTRACT

**Aim:** To compare ezetimibe/simvastatin combination therapy with intensified statin monotherapy as alternative treatment strategies to achieve the JBS-2 and NICE low-density-lipoprotein cholesterol (LDL-C) target of < 2 mmol/l for secondary prevention or JBS-2 LDL-C target of < 2 mmol/l for primary prevention in high-risk patients who have failed to reach target with simvastatin 40 mg.

**Methods:** Prospective, double-blind study in 34 UK primary care centres; 1748 patients with established cardiovascular disease (CVD), diabetes or high risk of CVD who had been taking simvastatin 40 mg for ≥ 6 weeks were screened and 786 (45%) with fasting LDL-C ≥ 2.0 mmol/l (and < 4.2 mmol/l) at screening and after a further 6-week run-in period on simvastatin 40 mg were randomised to ezetimibe/simvastatin 10/40 mg (as a combination tablet; n = 261), atorvastatin 40 mg (n = 263) or rosuvastatin 5 mg (n = 73) or 10 mg (n = 189) once daily for 6 weeks. Rosuvastatin dose was based on UK prescribing instructions. The primary outcome measure was the proportion of patients achieving LDL-C < 2 mmol/l at the end of the study.

**Results:** The percentage of patients (adjusted for baseline differences) achieving LDL-C < 2 mmol/l was 69.4% with ezetimibe/simvastatin 10/40 mg, compared with 33.5% for atorvastatin 40 mg (odds ratio 4.5 [95% CI 3.0 to 6.8]; p < 0.001) and 14.3% for rosuvastatin 5 or 10 mg (odds ratio 13.6 [95% CI 8.6 to 21.6]; p < 0.001). Similar results were observed for achievement of total cholesterol < 4.0 mmol/l. All study treatments were well tolerated.

**Conclusion:** Approximately 45% of patients screened had not achieved LDL-C < 2 mmol/l after ≥ 12 weeks of treatment with simvastatin 40 mg. In this group, treatment with ezetimibe/simvastatin 10/40 mg achieved target LDL-C levels in a
significantly higher proportion of patients during a 6-week period than switching to
either atorvastatin 40 mg or rosuvastatin 5–10 mg.

**Trial registration:** NCT 00462748 (www.clinicaltrials.gov)

**Key words:** atorvastatin, cholesterol absorption inhibition, cardiovascular disease,
ezetimibe/simvastatin, high risk, primary care, primary prevention, rosuvastatin

**Running title:** Ezetimibe/simvastatin combination for LDL-C targets

**Word count:** 3768

**WHAT THIS PAPER ADDS**

What’s known

- Guidelines for the prevention of cardiovascular disease (CVD) from the Joint
  British Societies (JBS-2) and National Institute for Health and Clinical Excellence
  (NICE) recommend cholesterol-lowering treatment to achieve low-density-
  lipoprotein cholesterol (LDL-C) levels < 2 mmol/l and total cholesterol
  < 4 mmol/l for secondary prevention in patients with established CVD (and in the
  case of NICE, in patients with diabetes).
- Current NICE guidelines recommend initial treatment with simvastatin 40 mg,
  which is inexpensive and clinically proven to reduce CVD outcomes. However,
  simvastatin 40 mg fails to achieve recommended LDL-C targets in more than half
  of patients.
- In patients for whom initial treatment with simvastatin 40 mg does not achieve
  LDL-C targets, alternative second-line options are to switch to a more potent
statin, or to initiate combination therapy with the cholesterol absorption inhibitor ezetimibe.

What’s new

- This is the first randomised double-blind clinical trial conducted in UK primary practice to compare second-line treatment strategies to reach LDL-C < 2 mmol/l in patients for whom initial treatment with simvastatin 40 mg has failed to achieve the guideline values.
- During the screening and run-in periods of the trial, simvastatin 40 mg treatment for ≥ 12 weeks failed to achieve the JBS-2 LDL-C target of < 2 mmol/l in nearly half (786/1748; 45%) of patients who were screened.
- Treatment with ezetimibe/simvastatin 10/40 mg led to a significantly higher proportion of patients achieving LDL-C < 2 mmol/l and total cholesterol < 4 mmol/l than did intensifying statin therapy by switching to atorvastatin 40 mg or rosuvastatin 5–10 mg.
INTRODUCTION

Cardiovascular disease (CVD) remains a major health issue in the UK, and still accounts for more than one-third of deaths each year (1). It is widely accepted that lowering serum cholesterol levels, and in particular low-density-lipoprotein cholesterol (LDL-C), reduces the risk of CVD irrespective of the method used to do so (2, 3). Consequently, reduction of LDL-C is a key component of healthcare strategies for CVD prevention, as implemented in the National Services Framework (NSF) in the UK (4, 5). Current Joint British Societies guidelines (JBS2) recommend target levels for LDL-C of < 2 mmol/l (< 77 mg/dl) and total cholesterol of < 4 mmol/l (< 155 mg/dl) for all individuals at high risk of CVD (whether for primary or secondary prevention) (6). These targets have recently been adopted in the latest National Institute for Health and Clinical Excellence (NICE) guidelines for secondary prevention in patients with established CVD and/or diabetes (7, 8). The NICE and JBS2 guidelines differ for primary prevention in high-risk patients without diabetes, in that the NICE guidance recommends treatment with simvastatin 40 mg but does not specify a target cholesterol level.

Original NICE guidance on the use of statins published in 2006 recommended the use of low-cost generic statins as first-line therapy to achieve target LDL-C levels (9); more recent NICE guidelines specify the use of simvastatin 40 mg (7, 8). Simvastatin 40 mg was proven to be effective in preventing CVD outcomes in major clinical trials such as the UK Heart Protection Study (10). The average LDL-C level in the UK adult population is about 3.6 mmol/l (11); given that simvastatin 40 mg typically lowers LDL-C by approximately 40% or 1 mmol/l (10), fewer than half of patients
requiring treatment are likely to reach LDL-C or total cholesterol targets with this first-line treatment (8). This raises the question of what the preferred second-line treatment option should be when simvastatin 40 mg has failed to achieve LDL-C < 2 mmol/l (< 77 mg/dl). Potential therapeutic strategies include increasing the dose of simvastatin to 80 mg, switching to a higher-potency statin, or combining statin treatment with the cholesterol absorption inhibitor ezetimibe.

We performed a randomised double-blind trial to compare three different treatment options for achieving LDL-C < 2 mmol/l (< 77 mg/dl) in primary and secondary prevention patients who had not attained target LDL-C with simvastatin 40 mg (the most commonly used generic statin when the study was initiated). The strategies tested were combination treatment with ezetimibe/simvastatin 10/40 mg, and intensifying statin monotherapy by switching to atorvastatin 40 mg or rosuvastatin 5–10 mg. As the majority of prescribing for cholesterol lowering in the UK takes place in primary care, the trial was conducted in this setting, including sites in England, Scotland, Wales and Northern Ireland. The proportion of patients reaching LDL-C < 2 mmol/l (< 77 mg/dl) was the pre-specified primary endpoint for the study, and the JBS-2 target for total cholesterol (< 4 mmol/l [< 155 mg/dl]) was a secondary endpoint; both targets were adopted by NICE guidance for secondary prevention in patients with established CVD with or without diabetes, published after the study was initiated. The safety and tolerability of each treatment were also assessed.
METHODS

Study design and patients

This was a randomised, double-blind, parallel-group study conducted at 34 primary care centres in the UK from March 2007 to May 2008, with full trial closure in November 2008. Patients eligible for inclusion were > 18 years of age, had established CVD or diabetes, or were at high risk of CVD (> 20% 10-year risk according to the Framingham scale), and had been taking simvastatin 40 mg for at least 6 weeks. Computer records at each study centre were searched to identify patients who were likely to fit the trial criteria, who were then invited for screening. Patients had to have a fasting LDL-C level between 2.0 and 4.2 mmol/l (77 and 162 mg/dl) at screening (visit 1) and at the end of the 6-week simvastatin 40 mg run-in period (visit 2). Patients also had to have a fasting triglyceride level < 3.7 mmol/l (< 328 mg/dl) and, for those with diabetes, haemoglobin A1C ≤ 9% at visit 1, and show ≥ 75% compliance with simvastatin medication (assessed by tablet count) during the run-in period.

Major exclusion criteria included known hypersensitivity to study medications, a history of liver disease, severe renal impairment (estimated creatinine clearance < 30 ml/min), uncontrolled endocrine or metabolic disease known to affect serum lipids or lipoproteins, previous or current alcohol abuse, elevated creatine kinase (> 10x upper limit of normal). Female patients were also excluded if they were pregnant, breastfeeding or not using adequate contraception. The study was conducted in accordance with Good Clinical Practice (GCP) standards and the Declaration of Helsinki, and was approved by the South-West Multi-centre Research Ethics
Committee. All patients gave written informed consent before participation in the study.

**Interventions**

Following screening, eligible patients entered a 6-week run-in period during which they received once-daily open-label simvastatin 40 mg. At the end of the run-in period (visit 2), blood samples were taken to assess lipid levels, and up to 7 days later eligible patients were randomised equally to once-daily treatment for 6 weeks with either ezetimibe/simvastatin 10/40 mg, atorvastatin 40 mg, or rosvuastatin 5 or 10 mg. The rosvuastatin dose was chosen on the basis of recommendations in the UK Summary of Product Characteristics that 5 mg should be the starting dose for patients over 70 years of age; for patients with creatinine clearance < 60 ml/min; and for patients of Asian ancestry or with other pre-disposing factors to myopathy switching from another statin.

**Randomisation and blinding**

To achieve balance between the treatment groups, patients were stratified according to their baseline fasting LDL-C levels (≥ 2.0 to < 2.5 mmol/l; ≥ 2.5 to < 3.0 mmol/l; and ≥ 3.0 to ≤ 4.2 mmol/l [77 to < 97 mg/dl; 97 to ≤ 116 mg/dl; and ≥ 116 to ≤ 162 mg/dl]), and by the clinical criteria that determine rosvuastatin dose. Randomisation was done centrally using an external Interactive Voice Response System, which assigned an allocation number to each patient, and patients were randomised equally to one of the three treatment arms within their stratification groups. Following treatment allocation, patients received active study medication and matching placebo tablets to ensure blinding. All patients and investigators remained
blinded to treatment allocation until the completion of the study.

**Measurement of blood lipids**

Blood samples for the measurement of fasting lipid levels (LDL-C, high-density-lipoprotein cholesterol [HDL-C], total cholesterol, triglycerides, and apoprotein [Apo] A1 and B) were taken following an 8- to 12-hour fast at screening, baseline and the end of the study (visits 1, 2 and 3, respectively). All blood samples were sent to a central laboratory for analysis (Quest Diagnostics, Heston, UK). LDL-C was estimated using the Friedewald equation.

Safety and tolerability assessments included monitoring for adverse experiences (which was performed throughout the study and included a follow-up telephone call 2 weeks after the study end), physical examination, measurement of vital signs, and laboratory assessments for haematology and blood chemistry.

**Outcome measures**

The primary efficacy variable was the overall percentage of patients (primary and secondary prevention) who attained the target fasting LDL-C level of < 2 mmol/l (< 77 mg/dl) at study end (defined as the last post-baseline assessment during the double-blind treatment period, regardless of whether the patient was receiving study medication at the time). Secondary efficacy endpoints were the percentage change from baseline to study end in LDL-C, total cholesterol and triglyceride levels, and the proportion of patients achieving total cholesterol < 4 mmol/l (< 155 mg/dl) at study end. Pre-specified exploratory efficacy variables included the percentage change from baseline in HDL-C, non-HDL-C, Apo-A1, Apo-B, total cholesterol:HDL-C ratio and...
Apo-B:Apo-A1 ratio, and the proportions of patients achieving LDL-C levels ≤ 1.8 mmol/l (< 70 mg/dl) and < 2.5 mmol/l (< 97 mg/dl) at study end.

**Statistical analysis**

The target sample size was 720 patients completing the study (240 patients per treatment group). This provided 85% power to detect a 15% difference in the primary endpoint between the ezetimibe/simvastatin group and the two comparator groups, using a two-sided 5% test and allowing for multiplicity. For the secondary endpoints of percentage change from baseline in fasting LDL-C and total cholesterol, 240 patients per treatment group gave more than 99% power to detect a difference between treatment groups of 10% (assuming a standard deviation for the reduction from baseline of 20%), using a two-sided 5% test and allowing for multiplicity.

Efficacy data were analysed using the Full Analysis Set population, which included all randomised patients who took at least one dose of double-blind study medication and had both baseline and post-baseline efficacy measurements. Safety data were analysed using the All-Patients-as-Treated (APaT) population, which included all randomised participants who received at least one dose of double-blind study medication.

For the primary efficacy outcome measure, the percentage of patients reaching the LDL-C target of < 2 mmol/l (< 77 mg/dl) was analysed using a logistic regression model with terms for treatment and stratum (in order to adjust for differences between treatment groups in baseline fasting LDL-C and in the clinical criteria determining rosvastatin dose). Odds ratio estimates and 95% confidence intervals (CIs) derived
from the logistic regression model were used to quantify the treatment effect.

Analysis of Variance (ANOVA) was used to investigate the percentage reduction in lipid parameters between baseline and post-baseline assessments, with terms for stratum and treatment group included in the model. Within- and between-treatment group least-squares means and 95% CIs were estimated from the models. The proportion of patients achieving other targets, and primary and secondary prevention patient subgroups, were also analysed using logistic regression with treatment and stratum included in the model. Multiplicity was addressed using a false discovery rate for the comparison of each treatment with the ezetimibe/simvastatin group, and using an ordered closed testing procedure for the secondary efficacy endpoints, undertaken only if the primary endpoint showed a significant effect. The percentage change in triglycerides was non-normally distributed, and was transformed to Tukey’s normalised ranks. The data were analysed using ANOVA with treatment and strata as factors. Hodges–Lehmann methodology was used to derive estimates of the pairwise differences in medians between the treatment groups and corresponding 95% CI. All statistical analyses were performed using SAS version 8.2.
RESULTS

Patient disposition and baseline characteristics

We screened a total of 1748 patients for the study (Figure 1). After the 6-week simvastatin run-in period, 786 patients (45%) met the eligibility criteria and were randomised to ezetimibe/simvastatin 10/40 mg (n = 261), atorvastatin 40 mg (n = 263) or rosvastatin 5–10 mg (n = 262) for 6 weeks. In the rosvastatin group, 73 patients (27.9%) received the 5 mg dose. The main reason for non-randomisation was LDL-C ≤ 2.0 mmol/l (≤ 77 mg/dl).

Six randomised patients did not take any study medication so were excluded from the APaT population used for the safety analyses (Figure 1). A further eight patients were excluded from the Full Analysis Set population because they had no post-baseline LDL-C or other lipid measurement. Hence a total of 772 patients were included in the efficacy analyses. Two patients with LDL-C level < 2.0 mmol/l at baseline were randomised to study medication in error (1.9 mmol/l [atorvastatin 40 mg] and 1.6 mmol/l [rosuvastatin 10 mg]).

Overall, 95.7% of patients completed the study. The number of treatment discontinuations was similar between treatment groups; adverse experiences were the main reason for treatment discontinuation. Average compliance with study medication was above 95%.

Treatment groups were well matched for patient baseline and demographic characteristics (Table 1). Overall, randomised patients had a mean age of 64.3 years;
two-thirds were male (66.5%) and the majority were Caucasian (98.6%).

**Efficacy**

**Primary efficacy outcome**

The primary outcome measure (primary efficacy variable) was the proportion of primary and secondary prevention patients achieving LDL-C < 2 mmol/l (< 77 mg/dl). The adjusted proportion of patients in the ezetimibe/simvastatin 10/40 mg group who achieved LDL-C < 2 mmol/l was 69.4%, compared with 33.5% in the atorvastatin 40 mg group (Figure 2). The corresponding odds ratio was 4.5 (95% CI: 3.0 to 6.8; \(p < 0.001\)) in favour of ezetimibe/simvastatin. Similarly, a significantly greater proportion of patients in the ezetimibe/simvastatin group achieved LDL-C < 2 mmol/l (< 77 mg/dl) compared with the rosvuastatin 5–10 mg group (69.4% vs 14.3%). The corresponding odds ratio was 13.6 (95% CI: 8.6 to 21.6; \(p < 0.001\)) in favour of ezetimibe/simvastatin. The unadjusted proportions of patients achieving LDL-C < 2 mmol/l (< 77 mg/dl) were 172/255 (67.5%) for ezetimibe/simvastatin, 94/259 (36.3%) for atorvastatin and 45/258 (17.4%) for rosvuastatin.

Results consistent with the full population were observed for achievement of LDL-C < 2 mmol/l (< 77 mg/dl) in each of the predefined baseline LDL-C strata (Figure 3), in the subset of patients who had clinical criteria qualifying for rosvuastatin 5 mg, for patients being treated for secondary prevention (i.e. with known CVD) and those treated for high-risk primary prevention (data not shown). A *post hoc* analysis of the primary efficacy variable by primary and secondary prevention subgroups yielded essentially identical results to the predefined analysis based on the overall population.
(Figure 3). There were no significant differences between primary and secondary prevention subgroups in the proportions of patients achieving LDL-C < 2 mmol/l in each treatment arm whether primary and secondary prevention were defined according to JBS-2 (subgroup effect $p = 0.750$) or NICE guidance (subgroup effect $p = 0.666$). The proportions of patients achieving LDL-C levels of $\leq 1.8$ mmol/l (< 70 mg/dl) and $< 2.5$ mmol/l (< 97 mg/dl) were also significantly higher with ezetimibe/simvastatin 10/40 mg than with atorvastatin 40 mg or rosuvastatin 5–10 mg.

**Secondary efficacy outcomes**

The adjusted proportion of primary and secondary prevention patients achieving total cholesterol $< 4$ mmol/l ($< 155$ mg/dl) was also significantly greater with ezetimibe/simvastatin 10/40 mg (57.7%) than with either atorvastatin 40 mg (31.8%; $p < 0.001$) or rosuvastatin 5–10 mg (14.5%; $p < 0.001$; Figure 2). The odds ratio for achievement of total cholesterol $< 4$ mmol/l was 2.9 (95% CI: 2.0 to 4.3; $p < 0.001$) in favour of ezetimibe/simvastatin over atorvastatin 40 mg, and 8.0 (95% CI: 5.2 to 12.4; $p < 0.001$) in favour of ezetimibe/simvastatin over rosuvastatin 5–10 mg.

Average percentage reductions from baseline in LDL-C and total cholesterol were significantly larger in patients receiving ezetimibe/simvastatin 10/40 mg than in those receiving either atorvastatin 40 mg or rosuvastatin 5–10 mg (Table 2). There were no significant between-treatment differences in changes in HDL-C or triglyceride levels (Table 2).

**Exploratory analyses**
Exploratory analyses showed significantly greater mean reductions from baseline in non-HDL-C, total cholesterol:HDL-C ratio, Apo B, and Apo B:Apo A1 ratio with ezetimibe/simvastatin 10/40 mg than with atorvastatin 40 mg or rosuvastatin 5–10 mg (Table 2).

**Tolerability**

All treatments were generally well tolerated. The proportion of patients reporting adverse experiences was similar in the three treatment groups, and consistent with the known safety profile of the treatments. The only individual adverse experience recorded in more than 3% of patients was diarrhoea with rosuvastatin (3.1%). The majority of events were not considered to be related to study medication (Table 3). There were few discontinuations due to adverse experiences (n = 21) or serious adverse experiences (n = 11) during double-blind treatment, and there were no notable differences in laboratory values or vital signs between treatment groups.
DISCUSSION

We designed this study to address a question of specific clinical relevance to UK general practice: when treatment with simvastatin 40 mg (the most commonly prescribed low acquisition cost statin) fails to bring high-risk patients to LDL-C < 2 mmol/l (< 77 mg/dl), what is the best next step to reach the target? This has become a more relevant question since recent NICE guidance warned that fewer than half of patients with CVD are likely to reach LDL-C or total cholesterol targets (< 2 mmol/l [< 77 mg/dl] and < 4 mmol/l [< 155 mg/dl], respectively) with simvastatin 40 mg (8). Our study confirms this guidance by showing that simvastatin 40 mg treatment for ≥ 12 weeks failed to achieve LDL-C < 2 mmol/l in nearly half (45%) of the high-risk primary and secondary prevention patients who were screened. In this group, a significantly higher proportion of patients reached LDL-C < 2 mmol/l (< 77 mg/dl) or total cholesterol < 4 mmol/l (< 155 mg/dl) with ezetimibe/simvastatin 10/40 mg than with either atorvastatin 40 mg or rosuvastatin 5–10 mg. Average percentage reductions from baseline in LDL-C and total cholesterol were significantly larger with ezetimibe/simvastatin 10/40 mg than either atorvastatin 40 mg or rosuvastatin 5–10 mg. All treatments were similarly well tolerated.

Findings in relation to other studies

Our study design encompasses a number of elements with specific relevance to current UK clinical practice: (i) we evaluated patients treated in the primary care setting who were receiving simvastatin 40 mg prior to study entry (a dose subsequently recommended by NICE guidance published after our study had started) (7, 8); (ii) the second-line options that we compared are those commonly used in current UK practice; that is, combination of simvastatin with inhibition of cholesterol
absorption by ezetimibe, and titration to two different statins considered by NICE to be of higher potency than simvastatin (atorvastatin and rosuvastatin); (iii) the primary endpoint of the JBS-2 target for LDL-C (< 2 mmol/l [< 77 mg/dl]) (6), which was selected to reflect the ‘target-oriented’ approach followed in UK clinical practice (8), has subsequently been adopted by NICE guidance for secondary prevention in patients with established CVD and/or diabetes (although not for primary prevention in patients without established CVD or diabetes) (7, 8).

Overall, we found that 69% of patients (primary and secondary prevention) achieved LDL-C < 2 mmol/l (< 77 mg/dl) with ezetimibe/simvastatin 10/40 mg, which was significantly greater than the proportion of patients reaching the target with atorvastatin 40 mg (34%) or rosuvastatin 5–10 mg (14%). Virtually identical findings were obtained when primary and secondary prevention subgroups were considered separately, irrespective of whether these were defined according to JBS-2 or NICE guidance (7, 8). This was by necessity a post hoc analysis as the NICE guidance was published after this study was initiated. Our findings were also robust across different baseline LDL-C strata and different LDL-C treatment targets (specifically, the ≤ 1.8 mmol/l [< 70 mg/dl] target recommended by the US National Cholesterol Education Program (12) and the < 2.5 mmol/l [< 97 mg/dl] target recommended in European guidelines (13)). LDL-C levels were reduced by approximately 26% from baseline with ezetimibe/simvastatin (compared with 11% for atorvastatin and 3% for rosuvastatin), and there were also significant reductions in total cholesterol and Apo-B. The cholesterol-lowering effects of combining ezetimibe and simvastatin relative to statin monotherapy observed in our study are broadly consistent with the results of a large number of ezetimibe clinical studies, as analysed in recent systematic
reviews/meta-analyses (14, 15). Our results are also congruent with those of the INFORCE study, a multicentre, randomised, open-label study in 424 patients hospitalised for an acute coronary event and taking a stable dose of a statin (≥ 6 weeks) (16). In that study, combination treatment with ezetimibe 10 mg plus simvastatin 40 mg over 12 weeks was associated with a mean 27% reduction from baseline in LDL-C; 70.1% of patients achieved LDL-C < 2.0 mmol/l (< 77 mg/dl). This suggests that the 6-week randomized treatment period used in this and previous studies (17) is sufficient to observe the full effects of lipid-lowering treatment on cholesterol levels. Indeed, a meta-analysis of ezetimibe clinical trials has shown that the cholesterol-lowering effects of ezetimibe/statin combinations and statin monotherapy observed over short-term treatment (6–8 weeks) are maintained at a similar level during long-term follow-up (up to 48 weeks) (15). A meta-analysis of 18 randomised clinical trials of ezetimibe involving more than 14,000 patients generally showed no significant safety issues with the addition of ezetimibe to statin therapy over up to 48 weeks (18).

Our study design selected patients who had not reached an LDL-C of < 2 mmol/l (< 77 mg/dl) despite at least 12 weeks’ treatment with simvastatin 40 mg. Other studies have addressed similar ‘non-responder’ groups, albeit with different treatment strategies (17). This patient group may simply represent those with a very high baseline LDL-C who are therefore unlikely to reach target with simvastatin monotherapy, or may represent relatively poor responders to statin therapy (19). Unfortunately, no reliable diagnostic for the latter group exists; an early hypothesis that indices of cholesterol absorption (e.g. campesterol/total cholesterol ratio) might be useful to predict which patients would respond better to statin therapy as compared
with ezetimibe has been refuted by recent clinical trials (20, 21). Nevertheless, irrespective of the underlying reason for the inadequate response to simvastatin, the practising physician is faced with a high-risk patient who has not achieved target LDL-C levels, and has to make a decision regarding the best next step to bring their patient to goal. Our study suggests that ezetimibe/simvastatin treatment is more effective than switching such a patient to a different, higher potency statin at the doses investigated. Unlike many studies that use percentage reduction in LDL-C as the primary endpoint, we believe that our pre-specified endpoint – percentage of patients achieving LDL-C target – is appropriate in the current target-driven clinical setting in the UK.

Limitations of the study

The primary endpoint of this study was achievement of LDL-C targets; whether the observed efficacy of ezetimibe/simvastatin translates into long-term reductions in morbidity and mortality that are superior to the proven benefits of statins such as atorvastatin and rosuvastatin is not answered by this study. Studies to assess whether LDL-C reduction with ezetimibe/statin combination translates into a reduction in clinical events are underway, including trials such as IMPROVE-IT, which will compare the effects of ezetimibe/simvastatin and simvastatin in patients with acute coronary syndromes (22). Pending endpoint data, the available evidence from meta-analyses of clinical outcome trials indicates that LDL-C reduction reduces CVD risk regardless of the method by which this is achieved (2, 3). The current study included clinical trial sites spread across the UK and we had intended to recruit a broadly representative population. The proportion of women was approximately one-third, and Asian and Black patients were relatively under-represented compared with the
UK population as a whole (Asian 4%; Black 2%) (23). Further studies in specific ethnic groups may be desirable.

The need to administer rosuvastatin in accordance with the UK Summary of Product Characteristics and the lack of an up-titration step in the study design meant that the doses used (5 or 10 mg) would be expected \textit{a priori} to exert a smaller effect on LDL-C than, for example, atorvastatin 40 mg. Previous studies would indicate that rosuvastatin 20 mg would be a more appropriate comparator for atorvastatin 40 mg (24). Indeed, higher doses of any of the statins employed in our study (e.g. atorvastatin 80 mg, rosuvastatin 20–40 mg or simvastatin 80 mg) would have provided larger reductions in LDL-C, although these tend to be of the order of only 6–8% for each doubling of the statin dose (24). Firm conclusions as to the efficacy of rosuvastatin compared with ezetimibe/simvastatin therefore cannot be drawn from the results of the present study. It should be noted, however, that current prescribing data from UK primary practice (IMS Disease Analyzer Mediplus, September 2009) indicates that the doses of rosuvastatin and atorvastatin used in this study are an accurate reflection of current prescribing patterns for patients switched between statins in UK primary practice (although the reasons for switching from simvastatin were not ascertained in the analysis of the IMS dataset). Thus, the vast majority (86%) of patients switched to rosuvastatin from a different statin are receiving the 5 or 10 mg doses (28% on 5 mg, 58% on 10 mg, 14% on 20 mg and 2% on 40 mg), and the majority (87%) of patients switched to atorvastatin from a different statin are receiving the 40 mg dose or lower (36% on 10 mg, 24% on 20 mg, 27% on 40 mg and 13% on 80 mg). Whether the safety and tolerability of maximum-dose statin monotherapy would have been similar to that of the ezetimibe/simvastatin
combination remains open to question and needs to be investigated in future studies. It should also be noted that the study did not assess the effects of combining ezetimibe with atorvastatin or rosuvastatin in patients not achieving target LDL-C goal with these drugs; further studies would be required to investigate the relative efficacy of this treatment approach.

**Potential implications and unanswered questions**

Our study shows that for high-risk patients who do not achieve desired targets for LDL-C with simvastatin 40 mg, a higher proportion will achieve LDL-C and total cholesterol targets with ezetimibe/simvastatin 10/40 mg than by switching to atorvastatin 40 mg or rosuvastatin 5–10 mg. A 2008 NICE Health Technology Assessment found that addition of ezetimibe to statin therapy was cost-effective compared with statin titration under specific scenarios, one of which was ezetimibe/simvastatin compared with switching to atorvastatin (14). Health economic studies are required to evaluate the budget implications for the NHS of routine prescribing of ezetimibe to achieve specified target LDL-C levels, given that NICE recommendations are not based solely on clinical efficacy, but also on cost-effectiveness and budget impact. Ultimately, data from clinical studies reporting cardiovascular events and mortality data associated with the addition of ezetimibe to statin treatment will be required to confirm the clinical benefits and safety profile of this therapeutic option.
AUTHOR CONTRIBUTIONS

TM is the guarantor; he was involved in discussions regarding the protocol, he was an investigator, he administrated the independent analysis and he was the Lead author of the writing committee. PH and RG were investigators and members of the writing committee. VA conducted the independent statistical analysis and was a member of the writing committee. RC and PR were involved in protocol design and clinical research operations and PR also contributed to the interpretation of the analysis. All authors had full access to all data and take responsibility for the integrity of the data and the accuracy of the data analysis, and approved the final version of the manuscript for publication.

ACKNOWLEDGEMENTS

The authors thank all of the investigators of the IN-PRACTICE study; Drs Mark Blagden, Charles Bundy, Tom Cahill, John Calvert, Johnathan Chapman, Glyn Chapman, Warwick Coulson, Frank Doig, Hugh Donnachie, Michael Duckworth, Alun George, Nigel Gough, David Haworth, Jerry Horn, Nick Jones, Neil Kerry, William Kleynhams, Chris Kyle, Teck Lee, Jennifer Litchfield, John Lovejoy, Richard Martin, Thomas Maxwell, Carol McKinnon, Michael Mutch, Juan Ochoa, Ian Orpen, Irina Pavel, Annette Pressman, Hilary Shaw, Hawys Thomas and Andrew Wijnberg.

The authors thank Dr Richard White (Oxford PharmaGenesis™ Ltd) for assistance in collating the comments of the writing committee on the initial draft manuscript (prepared by TM) and editing the final manuscript for submission. This role was funded by Merck Sharp & Dohme Ltd. Thanks are also due to Helen Tate (Sponsor...
Statistician) and Clare Mellon (Clinical Project Manager).

**FUNDING**

The study was supported by Merck Sharp & Dohme Ltd and Schering-Plough Ltd. The sponsor was involved in the study design, data collection and initial statistical analysis. The writing committee undertook an independent statistical analysis (VA) and were responsible for the interpretation of the data, the writing of the article and the decision to submit.
REFERENCES


**Table 1** Subject baseline and demographic characteristics (randomised population, \( n = 786 \))

<table>
<thead>
<tr>
<th></th>
<th>Ezetimibe/simvastatin 10/40 mg ((n = 261))</th>
<th>Atorvastatin 40 mg ((n = 263))</th>
<th>Rosuvastatin 5–10 mg ((n = 262))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>64.7 ± 8.7</td>
<td>64.2 ± 8.4</td>
<td>63.9 ± 8.6</td>
</tr>
<tr>
<td>≥ 70 years, ( n ) (%)</td>
<td>76 (29.1%)</td>
<td>76 (28.9%)</td>
<td>67 (25.6%)</td>
</tr>
<tr>
<td>Male, ( n ) (%)</td>
<td>160 (61.3%)</td>
<td>185 (70.3%)</td>
<td>178 (67.9%)</td>
</tr>
<tr>
<td>Race, ( n ) (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>254 (97.3%)</td>
<td>261 (99.2%)</td>
<td>257 (98.1%)</td>
</tr>
<tr>
<td>Asian</td>
<td>3 (1.1%)</td>
<td>0</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>Black</td>
<td>4 (1.5%)</td>
<td>0</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>2 (0.8%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td>Current smoker, ( n ) (%)</td>
<td>44 (16.9%)</td>
<td>55 (20.9%)</td>
<td>47 (17.9%)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>Current CVD/diabetes, n (%)</strong></td>
<td>138 (52.9%)</td>
<td>131 (49.8%)</td>
<td>136 (51.9%)</td>
</tr>
<tr>
<td><strong>High-risk CVD, n (%)</strong></td>
<td>123 (47.1%)</td>
<td>131 (49.8%)</td>
<td>126 (48.1%)</td>
</tr>
<tr>
<td><strong>Mean 10-year CVD risk&lt;sup&gt;a&lt;/sup&gt;</strong></td>
<td>36.3% ± 15.0%</td>
<td>37.4% ± 15.6%</td>
<td>33.5% ± 13.6%</td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Type 1, n (%)</strong></td>
<td>2 (0.8%)</td>
<td>1 (0.4%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td><strong>Type 2, n (%)</strong></td>
<td>40 (15.3%)</td>
<td>26 (9.9%)</td>
<td>32 (12.2%)</td>
</tr>
<tr>
<td>Fasting lipid levels, mmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LDL-C</strong></td>
<td>2.6 ± 0.4</td>
<td>2.6 ± 0.4</td>
<td>2.5 ± 0.4</td>
</tr>
<tr>
<td><strong>HDL-C</strong></td>
<td>1.4 ± 0.3</td>
<td>1.4 ± 0.3</td>
<td>1.4 ± 0.3</td>
</tr>
<tr>
<td><strong>Total cholesterol</strong></td>
<td>4.7 ± 0.5</td>
<td>4.7 ± 0.6</td>
<td>4.7 ± 0.6</td>
</tr>
<tr>
<td><strong>Triglycerides, median (range)</strong></td>
<td>1.6 (0.7 to 3.8)</td>
<td>1.5 (0.7 to 4.0)</td>
<td>1.6 (0.7 to 4.3)</td>
</tr>
</tbody>
</table>

Values are mean ± SD unless otherwise stated.

<sup>a</sup>Excluding secondary prevention.

CVD, cardiovascular disease; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol.
Table 2 Summary of secondary and exploratory efficacy outcome measures (Full Analysis Set, \(n = 772\))

<table>
<thead>
<tr>
<th></th>
<th>Ezetimibe/simvastatin 10/40 mg ((n = 255))</th>
<th>Atorvastatin 40 mg ((n = 259))</th>
<th>Rosuvastatin 5–10 mg ((n = 258))</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Percentage change from baseline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL-C</td>
<td>(-26.2 (-29.1 to -23.2))</td>
<td>(-11.1 (-14.0 to -8.2)**</td>
<td>(-3.0 (-5.9 to -0.1)**</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>(-16.3 (-18.2 to -14.5))</td>
<td>(-8.3 (-10.2 to -6.5)**</td>
<td>(-2.5 (-4.4 to -0.7)**</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>(-9.5 (-12.5 to -6.7))</td>
<td>(-8.1 (-11.8 to -2.9))</td>
<td>(-4.3 (-7.0 to 0.0))</td>
</tr>
<tr>
<td>HDL-C</td>
<td>(-1.4 (-2.9 to 0.0))</td>
<td>(-2.3 (-3.7 to -0.9))</td>
<td>(-0.1 (-1.5 to +1.3))</td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>(-22.2 (-24.7 to -19.6))</td>
<td>(-10.5 (-13.0 to -8.0)**</td>
<td>(-3.1 (-5.6 to -0.6)**</td>
</tr>
<tr>
<td>Total cholesterol:HDL-C ratio</td>
<td>(-14.4 (-16.4 to -12.4))</td>
<td>(-5.5 (-7.5 to -3.4)**</td>
<td>(-2.0 (-4.0 to 0.0)**</td>
</tr>
<tr>
<td>Apo A1</td>
<td>(-1.6 (-3.1 to -0.2))</td>
<td>(-4.5 (-5.9 to -3.1)**</td>
<td>(+0.6 (-0.8 to +2.1)**</td>
</tr>
<tr>
<td>Apo B</td>
<td>(-17.5 (-19.7 to -15.4))</td>
<td>(-9.0 (-11.1 to -6.9)**</td>
<td>(-3.2 (-5.3 to -1.1)**</td>
</tr>
<tr>
<td>Apo B:Apo A1 ratio</td>
<td>(-15.4 (-17.8 to -12.9))</td>
<td>(-3.8 (-6.2 to -1.4)**</td>
<td>(-3.1 (-5.5 to -0.7)**</td>
</tr>
</tbody>
</table>

\*\(p < 0.05\), \**\(p < 0.001\) vs ezetimibe/simvastatin 10/40 mg.

Data are least-squares mean (95% CI) percentage change from baseline, except for triglycerides which are median percent change (ANOVA
with treatment and strata as factors).

ANOVA, analysis of variance; Apo, apolipoprotein; CI, confidence interval; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol.
### Table 3. Tolerability of study treatments (All-Patients-as-Treated population, \( n = 780 \))

<table>
<thead>
<tr>
<th></th>
<th>Ezetimibe/simvastatin</th>
<th>Atorvastatin</th>
<th>Rosuvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10/40 mg ((n = 259))</td>
<td>40 mg ((n = 260))</td>
<td>5–10 mg ((n = 261))</td>
</tr>
<tr>
<td>Any AE</td>
<td>89 (34.4)</td>
<td>93 (35.8)</td>
<td>103 (39.5)</td>
</tr>
<tr>
<td>Drug-related AE</td>
<td>23 (8.9)</td>
<td>22 (8.5)</td>
<td>27 (10.3)</td>
</tr>
<tr>
<td>AE leading to study</td>
<td>7 (2.7)</td>
<td>5 (1.9)</td>
<td>9 (3.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious AE</td>
<td>4 (1.5)</td>
<td>2 (0.8)</td>
<td>5 (1.9)</td>
</tr>
<tr>
<td>Laboratory AE</td>
<td>5 (1.9)</td>
<td>3 (1.2)</td>
<td>1 (0.4)</td>
</tr>
</tbody>
</table>

Values are the number (%) of patients with at least one adverse experience (AE).

AEs reported were those occurring or worsening after the first dose of double-blind study medication and up to 14 days following the last dose of study medication (or 30 days for serious AEs).
FIGURE LEGENDS

Figure 1. Patient flow through study

†Patients could have more than one reason for randomisation failure. ‡No further details recorded. Randomised population (demographic and baseline characteristics); APaT, All-Patients-as-Treated (APaT) population (safety analyses); Full Analysis Set (efficacy analyses). ALT/AST, alanine aminotransferase/aspartate aminotransferase; LDL-C, low-density-lipoprotein cholesterol; ULN, upper limit of normal.

Figure 2. Proportion of patients achieving low-density-lipoprotein cholesterol (LDL-C) < 2 mmol/l (< 77 mg/dl) and total cholesterol < 4 mmol/l (< 155 mg/dl) for ezetimibe/simvastatin 10/40 mg compared with atorvastatin 40 mg and with rosuvastatin 5–10 mg (Full Analysis Set).

Data are presented as adjusted proportions (95% confidence interval [CI]). ** indicates **p < 0.001 vs ezetimibe/simvastatin 10/40 mg in a logistic regression model with treatment and LDL-C stratum as factors.

Figure 3. Subgroup analysis of proportion of patients achieving low-density-lipoprotein cholesterol LDL-C treatment goals for ezetimibe/simvastatin 10/40 mg compared with atorvastatin 40 mg and with rosuvastatin 5–10 mg (Full Analysis Set)

Data are adjusted proportion (95% CI), using logistic regression analysis with treatment and strata as factors. aJBS-2 definition of secondary prevention for patients with existing CVD or CVD and diabetes; primary prevention for high-risk patients or patients with diabetes but no CVD. bNICE definition of secondary prevention for patients with existing CVD and/or diabetes; primary prevention for high-risk patients without diabetes. Analysis was post hoc
because NICE treatment guidelines were published after the study was initiated. Predefined baseline LDL-C strata were ≥ 2.0 to < 2.5 mmol/l; ≥ 2.5 to < 3.0 mmol/l; and ≥ 3.0 to ≤ 4.2 mmol/l; the upper two strata were combined because there were too few patients in the highest stratum for analysis.

CI, confidence interval; JBS, Joint British Societies; LDL-C, low-density-lipoprotein cholesterol; NICE, National Institute for Health and Clinical Excellence.

** indicates **p < 0.001 vs ezetimibe/simvastatin 10/40 mg in a logistic regression model with treatment and LDL-C stratum as factors.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Randomised Population</th>
<th>Full Analysis Set</th>
<th>Completed Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe/simvastatin 10/40 mg</td>
<td>(n = 261)</td>
<td>(n = 255)</td>
<td>(n = 249)</td>
</tr>
<tr>
<td>Atorvastatin 40 mg</td>
<td>(n = 263)</td>
<td>(n = 259)</td>
<td>(n = 252)</td>
</tr>
<tr>
<td>Rosuvastin 5–10 mg</td>
<td>(n = 262)</td>
<td>(n = 258)</td>
<td>(n = 251)</td>
</tr>
</tbody>
</table>

Not randomised (n = 962)

Visit 1 (Week 0–7)
- Fasting LDL-C < 2 mmol/l (n = 604)
- Other (n = 189)

Visit 2 (Week –1)
- Fasting LDL-C < 2 mmol/l (n = 141)
- Fasting LDL-C > 4.2 mmol/l (n = 3)
- Compliance < 75% (n = 7)
- ALT/AST > 3 x ULN (n = 2)
- Creatine kinase > 10 x ULN (n = 3)
- Did not meet eligibility criteria (n = 126)
Ezetimibe/simvastatin 10/40 mg (n = 255)
Atorvastatin 40 mg (n = 259)
Rosuvastatin 5–10 mg (n = 258)

Patients reaching target (%)

LDL-C < 2.0 mmol/l
Total cholesterol < 4.0 mmol/l

86x56mm (600 x 600 DPI)
For Peer Review Only

International Journal of Clinical Practice

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

78x106mm (600 x 600 DPI)
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

Authors

Terry McCormack, Peter Harvey, Richard Gaunt, Victoria Allgar, Robert Chipperfield, Paul Robinson

Affiliations

1 General Practitioner, Whitby Group Practice, Spring Vale Medical Centre, Whitby YO21 1SD

2 General Practitioner, The Crouch Oak Family Practice, 45 Station Road, Addlestone KT15 2BH

3 General Practitioner, Rowden Medical Practice, Rowden Hill, Chippenham SN15 2SB

4 Senior Lecturer in Medical Statistics, Hull York Medical School, University of York, York YO10 5DD

5 Strategic Healthcare Development Manager, Schering-Plough Ltd, Welwyn Garden City AL7 1TW

6 Medical Director, Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon EN11 9BU

Corresponding author:

Terry McCormack, Whitby Group Practice, Spring Vale Medical Centre, Whitby YO21 1SD
Disclosures

TM has received research grants, educational grants and advisory board honoraria from AstraZeneca, Merck Sharp & Dohme and Schering-Plough, and received expenses from Pfizer to give a lecture. PH has received research grants and consultancy or speaking honoraria from AstraZeneca, Merck Sharp & Dohme, Pfizer and Schering-Plough. RG has received advisory board honoraria from Merck Sharp & Dohme. RC is an employee of Schering-Plough. PR is an employee of Merck Sharp & Dohme. VA has no potential conflicts of interest to declare.
ABSTRACT

Aim: To compare ezetimibe/simvastatin combination therapy with intensified statin monotherapy as alternative treatment strategies to achieve the JBS-2 and NICE low-density-lipoprotein cholesterol (LDL-C) target of < 2 mmol/l for secondary prevention or JBS-2 LDL-C target of < 2 mmol/l for primary prevention in high-risk patients who have failed to reach target with simvastatin 40 mg.

Methods: Prospective, double-blind study in 34 UK primary care centres; 1748 patients with established cardiovascular disease (CVD), diabetes or high risk of CVD who had been taking simvastatin 40 mg for ≥ 6 weeks were screened and 786 (45%) with fasting LDL-C ≥ 2.0 mmol/l (and < 4.2 mmol/l) at screening and after a further 6-week run-in period on simvastatin 40 mg were randomised to ezetimibe/simvastatin 10/40 mg (as a combination tablet; n = 261), atorvastatin 40 mg (n = 263) or rosuvastatin 5 mg (n = 73) or 10 mg (n = 189) once daily for 6 weeks. Rosuvastatin dose was based on UK prescribing instructions. The primary outcome measure was the proportion of patients achieving LDL-C < 2 mmol/l at the end of the study.

Results: The percentage of patients (adjusted for baseline differences) achieving LDL-C < 2 mmol/l was 69.4% with ezetimibe/simvastatin 10/40 mg, compared with 33.5% for atorvastatin 40 mg (odds ratio 4.5 [95% CI 3.0 to 6.8]; p < 0.001) and 14.3% for rosuvastatin 5 or 10 mg (odds ratio 13.6 [95% CI 8.6 to 21.6]; p < 0.001). Similar results were observed for achievement of total cholesterol < 4.0 mmol/l. All study treatments were well tolerated.

Conclusion: Approximately 45% of patients screened had not achieved LDL-C < 2 mmol/l after ≥ 12 weeks of treatment with simvastatin 40 mg. In this group, treatment with ezetimibe/simvastatin 10/40 mg achieved target LDL-C levels in a
significantly higher proportion of patients during a 6-week period than switching to either atorvastatin 40 mg or rosvastatin 5–10 mg.

Trial registration: NCT 00462748 (www.clinicaltrials.gov)

Key words: atorvastatin, cholesterol absorption inhibition, cardiovascular disease, ezetimibe/simvastatin, high risk, primary care, primary prevention, rosvastatin

Running title: Ezetimibe/simvastatin combination for LDL-C targets

Word count: 3768

WHAT THIS PAPER ADDS

What’s known

- Guidelines for the prevention of cardiovascular disease (CVD) from the Joint British Societies (JBS-2) and National Institute for Health and Clinical Excellence (NICE) recommend cholesterol-lowering treatment to achieve low-density-lipoprotein cholesterol (LDL-C) levels < 2 mmol/l and total cholesterol < 4 mmol/l for secondary prevention in patients with established CVD (and in the case of NICE, in patients with diabetes).
- Current NICE guidelines recommend initial treatment with simvastatin 40 mg, which is inexpensive and clinically proven to reduce CVD outcomes. However, simvastatin 40 mg fails to achieve recommended LDL-C targets in more than half of patients.
- In patients for whom initial treatment with simvastatin 40 mg does not achieve LDL-C targets, alternative second-line options are to switch to a more potent...
statin, or to initiate combination therapy with the cholesterol absorption inhibitor ezetimibe.

What’s new

- This is the first randomised double-blind clinical trial conducted in UK primary practice to compare second-line treatment strategies to reach LDL-C < 2 mmol/l in patients for whom initial treatment with simvastatin 40 mg has failed to achieve the guideline values.

  - During the screening and run-in periods of the trial, simvastatin 40 mg treatment for $\geq$ 12 weeks failed to achieve the JBS-2 LDL-C target of < 2 mmol/l in nearly half (786/1748; 45%) of patients who were screened.

- Treatment with ezetimibe/simvastatin 10/40 mg led to a significantly higher proportion of patients achieving LDL-C < 2 mmol/l and total cholesterol < 4 mmol/l than did intensifying statin therapy by switching to atorvastatin 40 mg or rosuvastatin 5–10 mg.
INTRODUCTION

Cardiovascular disease (CVD) remains a major health issue in the UK, and still accounts for more than one-third of deaths each year (1). It is widely accepted that lowering serum cholesterol levels, and in particular low-density-lipoprotein cholesterol (LDL-C), reduces the risk of CVD irrespective of the method used to do so (2, 3). Consequently, reduction of LDL-C is a key component of healthcare strategies for CVD prevention, as implemented in the National Services Framework (NSF) in the UK (4, 5). Current Joint British Societies guidelines (JBS-2) recommend target levels for LDL-C of < 2 mmol/l (< 77 mg/dl) and total cholesterol of < 4 mmol/l (< 155 mg/dl) for all individuals at high risk of CVD (whether for primary or secondary prevention) (6). These targets have recently been adopted in the latest National Institute for Health and Clinical Excellence (NICE) guidelines for secondary prevention in patients with established CVD and/or diabetes (7, 8). The NICE and JBS-2 guidelines differ for primary prevention in high-risk patients without diabetes, in that the NICE guidance recommends treatment with simvastatin 40 mg but does not specify a target cholesterol level.

Original NICE guidance on the use of statins published in 2006 recommended the use of low-cost generic statins as first-line therapy to achieve target LDL-C levels (9); more recent NICE guidelines specify the use of simvastatin 40 mg (7, 8). Simvastatin 40 mg was proven to be effective in preventing CVD outcomes in major clinical trials such as the UK Heart Protection Study (10). The average LDL-C level in the UK adult population is about 3.6 mmol/l (11); given that simvastatin 40 mg typically lowers LDL-C by approximately 40% or 1 mmol/l (10), fewer than half of patients...
requiring treatment are likely to reach LDL-C or total cholesterol targets with this first-line treatment (8). This raises the question of what the preferred second-line treatment option should be when simvastatin 40 mg has failed to achieve LDL-C < 2 mmol/l (< 77 mg/dl). Potential therapeutic strategies include increasing the dose of simvastatin to 80 mg, switching to a higher-potency statin, or combining statin treatment with the cholesterol absorption inhibitor ezetimibe.

We performed a randomised double-blind trial to compare three different treatment options for achieving LDL-C < 2 mmol/l (< 77 mg/dl) in primary and secondary prevention patients who had not attained target LDL-C with simvastatin 40 mg (the most commonly used generic statin when the study was initiated). The strategies tested were combination treatment with ezetimibe/simvastatin 10/40 mg, and intensifying statin monotherapy by switching to atorvastatin 40 mg or rosuvastatin 5–10 mg. As the majority of prescribing for cholesterol lowering in the UK takes place in primary care, the trial was conducted in this setting, including sites in England, Scotland, Wales and Northern Ireland. The proportion of patients reaching LDL-C < 2 mmol/l (< 77 mg/dl) was the pre-specified primary endpoint for the study, and the JBS-2 target for total cholesterol (< 4 mmol/l [< 155 mg/dl]) was a secondary endpoint; both targets were adopted by NICE guidance for secondary prevention in patients with established CVD with or without diabetes, published after the study was initiated. The safety and tolerability of each treatment were also assessed.
METHODS

Study design and patients

This was a randomised, double-blind, parallel-group study conducted at 34 primary care centres in the UK from March 2007 to May 2008, with full trial closure in November 2008. Patients eligible for inclusion were > 18 years of age, had established CVD or diabetes, or were at high risk of CVD (> 20% 10-year risk according to the Framingham scale), and had been taking simvastatin 40 mg for at least 6 weeks. Computer records at each study centre were searched to identify patients who were likely to fit the trial criteria, who were then invited for screening.

Patients had to have a fasting LDL-C level between 2.0 and 4.2 mmol/l (77 and 162 mg/dl) at screening (visit 1) and at the end of the 6-week simvastatin 40 mg run-in period (visit 2). Patients also had to have a fasting triglyceride level < 3.7 mmol/l (< 328 mg/dl) and, for those with diabetes, haemoglobin A₁C ≤ 9% at visit 1, and show ≥ 75% compliance with simvastatin medication (assessed by tablet count) during the run-in period.

Major exclusion criteria included known hypersensitivity to study medications, a history of liver disease, severe renal impairment (estimated creatinine clearance < 30 ml/min), uncontrolled endocrine or metabolic disease known to affect serum lipids or lipoproteins, previous or current alcohol abuse, elevated creatine kinase (> 10x upper limit of normal). Female patients were also excluded if they were pregnant, breastfeeding or not using adequate contraception. The study was conducted in accordance with Good Clinical Practice (GCP) standards and the Declaration of Helsinki, and was approved by the South-West Multi-centre Research Ethics Committee.
Committee. All patients gave written informed consent before participation in the study.

**Interventions**

Following screening, eligible patients entered a 6-week run-in period during which they received once-daily open-label simvastatin 40 mg. At the end of the run-in period (visit 2), blood samples were taken to assess lipid levels, and up to 7 days later eligible patients were randomised equally to once-daily treatment for 6 weeks with either ezetimibe/simvastatin 10/40 mg, atorvastatin 40 mg, or rosuvastatin 5 or 10 mg. The rosuvastatin dose was chosen on the basis of recommendations in the UK Summary of Product Characteristics that 5 mg should be the starting dose for patients over 70 years of age; for patients with creatinine clearance < 60 ml/min; and for patients of Asian ancestry or with other pre-disposing factors to myopathy switching from another statin.

**Randomisation and blinding**

To achieve balance between the treatment groups, patients were stratified according to their baseline fasting LDL-C levels (≥ 2.0 to < 2.5 mmol/l; ≥ 2.5 to < 3.0 mmol/l; and ≥ 3.0 to ≤ 4.2 mmol/l [77 to < 97 mg/dl; 97 to ≤ 116 mg/dl; and ≥ 116 to ≤ 162 mg/dl]), and by the clinical criteria that determine rosuvastatin dose. Randomisation was done centrally using an external Interactive Voice Response System, which assigned an allocation number to each patient, and patients were randomised equally to one of the three treatment arms within their stratification groups. Following treatment allocation, patients received active study medication and matching placebo tablets to ensure blinding. All patients and investigators remained
blinded to treatment allocation until the completion of the study.

**Measurement of blood lipids**

Blood samples for the measurement of fasting lipid levels (LDL-C, high-density-lipoprotein cholesterol [HDL-C], total cholesterol, triglycerides, and apoprotein [Apo] A1 and B) were taken following an 8- to 12-hour fast at screening, baseline and the end of the study (visits 1, 2 and 3, respectively). All blood samples were sent to a central laboratory for analysis (Quest Diagnostics, Heston, UK). LDL-C was estimated using the Friedewald equation.

Safety and tolerability assessments included monitoring for adverse experiences (which was performed throughout the study and included a follow-up telephone call 2 weeks after the study end), physical examination, measurement of vital signs, and laboratory assessments for haematology and blood chemistry.

**Outcome measures**

The primary efficacy variable was the overall percentage of patients (primary and secondary prevention) who attained the target fasting LDL-C level of < 2 mmol/l (< 77 mg/dl) at study end (defined as the last post-baseline assessment during the double-blind treatment period, regardless of whether the patient was receiving study medication at the time). Secondary efficacy endpoints were the percentage change from baseline to study end in LDL-C, total cholesterol and triglyceride levels, and the proportion of patients achieving total cholesterol < 4 mmol/l (< 155 mg/dl) at study end. Pre-specified exploratory efficacy variables included the percentage change from baseline in HDL-C, non-HDL-C, Apo-A1, Apo-B, total cholesterol:HDL-C ratio and
Apo-B:Apo-A1 ratio, and the proportions of patients achieving LDL-C levels ≤ 1.8 mmol/l (< 70 mg/dl) and < 2.5 mmol/l (< 97 mg/dl) at study end.

**Statistical analysis**

The target sample size was 720 patients completing the study (240 patients per treatment group). This provided 85% power to detect a 15% difference in the primary endpoint between the ezetimibe/simvastatin group and the two comparator groups, using a two-sided 5% test and allowing for multiplicity. For the secondary endpoints of percentage change from baseline in fasting LDL-C and total cholesterol, 240 patients per treatment group gave more than 99% power to detect a difference between treatment groups of 10% (assuming a standard deviation for the reduction from baseline of 20%), using a two-sided 5% test and allowing for multiplicity.

Efficacy data were analysed using the Full Analysis Set population, which included all randomised patients who took at least one dose of double-blind study medication and had both baseline and post-baseline efficacy measurements. Safety data were analysed using the All-Patients-as-Treated (APaT) population, which included all randomised participants who received at least one dose of double-blind study medication.

For the primary efficacy outcome measure, the percentage of patients reaching the LDL-C target of < 2 mmol/l (< 77 mg/dl) was analysed using a logistic regression model with terms for treatment and stratum (in order to adjust for differences between treatment groups in baseline fasting LDL-C and in the clinical criteria determining rosvastatin dose). Odds ratio estimates and 95% confidence intervals (CIs) derived
from the logistic regression model were used to quantify the treatment effect.

Analysis of Variance (ANOVA) was used to investigate the percentage reduction in lipid parameters between baseline and post-baseline assessments, with terms for stratum and treatment group included in the model. Within- and between-treatment group least-squares means and 95% CIs were estimated from the models. The proportion of patients achieving other targets, and primary and secondary prevention patient subgroups, were also analysed using logistic regression with treatment and stratum included in the model. Multiplicity was addressed using a false discovery rate for the comparison of each treatment with the ezetimibe/simvastatin group, and using an ordered closed testing procedure for the secondary efficacy endpoints, undertaken only if the primary endpoint showed a significant effect. The percentage change in triglycerides was non-normally distributed, and was transformed to Tukey’s normalised ranks. The data were analysed using ANOVA with treatment and strata as factors. Hodges–Lehmann methodology was used to derive estimates of the pairwise differences in medians between the treatment groups and corresponding 95% CI. All statistical analyses were performed using SAS version 8.2.
RESULTS

Patient disposition and baseline characteristics

We screened a total of 1748 patients for the study (Figure 1). After the 6-week simvastatin run-in period, 786 patients (45%) met the eligibility criteria and were randomised to ezetimibe/simvastatin 10/40 mg (n = 261), atorvastatin 40 mg (n = 263) or rosvastatin 5–10 mg (n = 262) for 6 weeks. In the rosvastatin group, 73 patients (27.9%) received the 5 mg dose. The main reason for non-randomisation was LDL-C ≤ 2.0 mmol/l (≤ 77 mg/dl).

Six randomised patients did not take any study medication so were excluded from the APaT population used for the safety analyses (Figure 1). A further eight patients were excluded from the Full Analysis Set population because they had no post-baseline LDL-C or other lipid measurement. Hence a total of 772 patients were included in the efficacy analyses. Two patients with LDL-C level < 2.0 mmol/l at baseline were randomised to study medication in error (1.9 mmol/l [atorvastatin 40 mg] and 1.6 mmol/l [rosuvastatin 10 mg]).

Overall, 95.7% of patients completed the study. The number of treatment discontinuations was similar between treatment groups; adverse experiences were the main reason for treatment discontinuation. Average compliance with study medication was above 95%.

Treatment groups were well matched for patient baseline and demographic characteristics (Table 1). Overall, randomised patients had a mean age of 64.3 years;
two-thirds were male (66.5%) and the majority were Caucasian (98.6%).

**Efficacy**

**Primary efficacy outcome**

The primary outcome measure (primary efficacy variable) was the proportion of patients achieving LDL-C < 2 mmol/l (< 77 mg/dl). The adjusted proportion of patients in the ezetimibe/simvastatin group who achieved LDL-C < 2 mmol/l was 69.4%, compared with 33.5% in the atorvastatin 40 mg group (Figure 2). The corresponding odds ratio was 4.5 (95% CI: 3.0 to 6.8; \( p < 0.001 \)) in favour of ezetimibe/simvastatin. Similarly, a significantly greater proportion of patients in the ezetimibe/simvastatin group achieved LDL-C < 2 mmol/l (< 77 mg/dl) compared with the rosuvastatin 5–10 mg group (69.4% vs 14.3%). The corresponding odds ratio was 13.6 (95% CI: 8.6 to 21.6; \( p < 0.001 \)) in favour of ezetimibe/simvastatin. The unadjusted proportions of patients achieving LDL-C < 2 mmol/l (< 77 mg/dl) were 172/255 (67.5%) for ezetimibe/simvastatin, 94/259 (36.3%) for atorvastatin and 45/258 (17.4%) for rosuvastatin.

Results consistent with the full population were observed for achievement of LDL-C < 2 mmol/l (< 77 mg/dl) in each of the predefined baseline LDL-C strata (Figure 3), in the subset of patients who had clinical criteria qualifying for rosuvastatin 5 mg, for patients being treated for secondary prevention (i.e. with known CVD) and those treated for high-risk primary prevention (data not shown). A post hoc analysis of the primary efficacy variable by primary and secondary prevention subgroups yielded essentially identical results to the predefined analysis based on the overall population.
There were no significant differences between primary and secondary prevention subgroups in the proportions of patients achieving LDL-C < 2 mmol/l in each treatment arm whether primary and secondary prevention were defined according to JBS-2 (subgroup effect $p = 0.750$) or NICE guidance (subgroup effect $p = 0.666$). The proportions of patients achieving LDL-C levels of < 1.8 mmol/l (< 70 mg/dl) and < 2.5 mmol/l (< 97 mg/dl) were also significantly higher with ezetimibe/simvastatin 10/40 mg than with atorvastatin 40 mg or rosuvastatin 5–10 mg.

Secondary efficacy outcomes

The adjusted proportion of primary and secondary prevention patients achieving total cholesterol < 4 mmol/l (< 155 mg/dl) was also significantly greater with ezetimibe/simvastatin 10/40 mg (57.7%) than with either atorvastatin 40 mg (31.8%; $p < 0.001$) or rosuvastatin 5–10 mg (14.5%; $p < 0.001$; Figure 2). The odds ratio for achievement of total cholesterol < 4 mmol/l was 2.9 (95% CI: 2.0 to 4.3; $p < 0.001$) in favour of ezetimibe/simvastatin over atorvastatin 40 mg, and 8.0 (95% CI: 5.2 to 12.4; $p < 0.001$) in favour of ezetimibe/simvastatin over rosuvastatin 5–10 mg.

Average percentage reductions from baseline in LDL-C and total cholesterol were significantly larger in patients receiving ezetimibe/simvastatin 10/40 mg than in those receiving either atorvastatin 40 mg or rosuvastatin 5–10 mg (Table 2). There were no significant between-treatment differences in changes in HDL-C or triglyceride levels (Table 2).

Exploratory analyses
Exploratory analyses showed significantly greater mean reductions from baseline in non-HDL-C, total cholesterol:HDL-C ratio, Apo B, and Apo B:Apo A1 ratio with ezetimibe/simvastatin 10/40 mg than with atorvastatin 40 mg or rosuvastatin 5–10 mg (Table 2).

**Tolerability**

All treatments were generally well tolerated. The proportion of patients reporting adverse experiences was similar in the three treatment groups, and consistent with the known safety profile of the treatments. The only individual adverse experience recorded in more than 3% of patients was diarrhoea with rosuvastatin (3.1%). The majority of events were not considered to be related to study medication (Table 3).

There were few discontinuations due to adverse experiences (n = 21) or serious adverse experiences (n = 11) during double-blind treatment, and there were no notable differences in laboratory values or vital signs between treatment groups.
DISCUSSION

We designed this study to address a question of specific clinical relevance to UK general practice: when treatment with simvastatin 40 mg (the most commonly prescribed low acquisition cost statin) fails to bring high-risk patients to LDL-C < 2 mmol/l (< 77 mg/dl), what is the best next step to reach the target? This has become a more relevant question since recent NICE guidance warned that fewer than half of patients with CVD are likely to reach LDL-C or total cholesterol targets (< 2 mmol/l [< 77 mg/dl] and < 4 mmol/l [< 155 mg/dl], respectively) with simvastatin 40 mg (8). Our study confirms this guidance by showing that simvastatin 40 mg treatment for ≥ 12 weeks failed to achieve LDL-C < 2 mmol/l in nearly half (45%) of the high-risk primary and secondary prevention patients who were screened.

In this group, a significantly higher proportion of patients reached LDL-C < 2 mmol/l (< 77 mg/dl) or total cholesterol < 4 mmol/l (< 155 mg/dl) with ezetimibe/simvastatin 10/40 mg than with either atorvastatin 40 mg or rosuvastatin 5–10 mg. Average percentage reductions from baseline in LDL-C and total cholesterol were significantly larger with ezetimibe/simvastatin 10/40 mg than either atorvastatin 40 mg or rosuvastatin 5–10 mg. All treatments were similarly well tolerated.

Findings in relation to other studies

Our study design encompasses a number of elements with specific relevance to current UK clinical practice: (i) we evaluated patients treated in the primary care setting who were receiving simvastatin 40 mg prior to study entry (a dose subsequently recommended by NICE guidance published after our study had started) (7, 8); (ii) the second-line options that we compared are those commonly used in current UK practice; that is, combination of simvastatin with inhibition of cholesterol
For Peer Review Only

absorption by ezetimibe, and titration to two different statins considered by NICE
to be of higher potency than simvastatin (atorvastatin and rosuvastatin); (iii) the primary
episode of the JBS-2 target for LDL-C (< 2 mmol/l [< 77 mg/dl]) (6), which was
selected to reflect the ‘target-oriented’ approach followed in UK clinical practice (8),
has subsequently been adopted by NICE guidance for secondary prevention in
patients with established CVD and/or diabetes (although not for primary prevention in
patients without established CVD or diabetes) (7, 8).

Overall, we found that 69% of patients (primary and secondary prevention) achieved
LDL-C < 2 mmol/l (< 77 mg/dl) with ezetimibe/simvastatin 10/40 mg, which was
significantly greater than the proportion of patients reaching the target with
atorvastatin 40 mg (34%) or rosuvastatin 5–10 mg (14%). Virtually identical findings
were obtained when primary and secondary prevention subgroups were considered
separately, irrespective of whether these were defined according to JBS-2 or NICE
guidance (7, 8). This was by necessity a post hoc analysis as the NICE guidance was
published after this study was initiated. Our findings were also robust across different
baseline LDL-C strata and different LDL-C treatment targets (specifically, the
≤ 1.8 mmol/l [< 70 mg/dl] target recommended by the US National Cholesterol
Education Program (12) and the < 2.5 mmol/l [< 97 mg/dl] target recommended in
European guidelines (13)). LDL-C levels were reduced by approximately 26% from
baseline with ezetimibe/simvastatin (compared with 11% for atorvastatin and 3% for
rosuvastatin), and there were also significant reductions in total cholesterol and Apo-
B. The cholesterol-lowering effects of combining ezetimibe and simvastatin relative
to statin monotherapy observed in our study are broadly consistent with the results of
a large number of ezetimibe clinical studies, as analysed in recent systematic

18
reviews/meta-analyses (14, 15). Our results are also congruent with those of the
INFORCE study, a multicentre, randomised, open-label study in 424 patients
hospitalised for an acute coronary event and taking a stable dose of a statin (≥ 6
weeks) (16). In that study, combination treatment with ezetimibe 10 mg plus
simvastatin 40 mg over 12 weeks was associated with a mean 27% reduction from
baseline in LDL-C; 70.1% of patients achieved LDL-C < 2.0 mmol/l (< 77 mg/dl).
This suggests that the 6-week randomized treatment period used in this and previous
studies (17) is sufficient to observe the full effects of lipid-lowering treatment on
cholesterol levels. Indeed, a meta-analysis of ezetimibe clinical trials has shown that
the cholesterol-lowering effects of ezetimibe/statin combinations and statin
monotherapy observed over short-term treatment (6–8 weeks) are maintained at a
similar level during long-term follow-up (up to 48 weeks) (15). A meta-analysis of 18
randomised clinical trials of ezetimibe involving more than 14,000 patients generally
showed no significant safety issues with the addition of ezetimibe to statin therapy
over up to 48 weeks (18).

Our study design selected patients who had not reached an LDL-C of < 2 mmol/l
(< 77 mg/dl) despite at least 12 weeks’ treatment with simvastatin 40 mg. Other
studies have addressed similar ‘non-responder’ groups, albeit with different treatment
strategies (17). This patient group may simply represent those with a very high
baseline LDL-C who are therefore unlikely to reach target with simvastatin
monotherapy, or may represent relatively poor responders to statin therapy (19).

Unfortunately, no reliable diagnostic for the latter group exists; an early hypothesis
that indices of cholesterol absorption (e.g. campesterol/total cholesterol ratio) might
be useful to predict which patients would respond better to statin therapy as compared
with ezetimibe has been refuted by recent clinical trials (20, 21). Nevertheless, irrespective of the underlying reason for the inadequate response to simvastatin, the practising physician is faced with a high-risk patient who has not achieved target LDL-C levels, and has to make a decision regarding the best next step to bring their patient to goal. Our study suggests that ezetimibe/simvastatin treatment is more effective than switching such a patient to a different, higher potency statin at the doses investigated. Unlike many studies that use percentage reduction in LDL-C as the primary endpoint, we believe that our pre-specified endpoint – percentage of patients achieving LDL-C target – is appropriate in the current target-driven clinical setting in the UK.

**Limitations of the study**

The primary endpoint of this study was achievement of LDL-C targets; whether the observed efficacy of ezetimibe/simvastatin translates into long-term reductions in morbidity and mortality that are superior to the proven benefits of statins such as atorvastatin and rosuvastatin is not answered by this study. Studies to assess whether LDL-C reduction with ezetimibe/statin combination translates into a reduction in clinical events are underway, including trials such as IMPROVE-IT, which will compare the effects of ezetimibe/simvastatin and simvastatin in patients with acute coronary syndromes (22). Pending endpoint data, the available evidence from meta-analyses of clinical outcome trials indicates that LDL-C reduction reduces CVD risk regardless of the method by which this is achieved (2, 3). The current study included clinical trial sites spread across the UK and we had intended to recruit a broadly representative population. The proportion of women was approximately one-third, and Asian and Black patients were relatively under-represented compared with the
UK population as a whole (Asian 4%; Black 2%) (23). Further studies in specific ethnic groups may be desirable.

The need to administer rosuvastatin in accordance with the UK Summary of Product Characteristics and the lack of an up-titration step in the study design meant that the doses used (5 or 10 mg) would be expected a priori to exert a smaller effect on LDL-C than, for example, atorvastatin 40 mg. Previous studies would indicate that rosuvastatin 20 mg would be a more appropriate comparator for atorvastatin 40 mg (24). Indeed, higher doses of any of the statins employed in our study (e.g. atorvastatin 80 mg, rosuvastatin 20–40 mg or simvas tatin 80 mg) would have provided larger reductions in LDL-C, although these tend to be of the order of only 6–8% for each doubling of the statin dose (24). Firm conclusions as to the efficacy of rosuvastatin compared with ezetimibe/simvastatin therefore cannot be drawn from the results of the present study. It should be noted, however, that current prescribing data from UK primary practice (IMS Disease Analyzer Mediplus, September 2009) indicates that the doses of rosuvastatin and atorvastatin used in this study are an accurate reflection of current prescribing patterns for patients switched between statins in UK primary practice (although the reasons for switching from simvastatin were not ascertained in the analysis of the IMS dataset). Thus, the vast majority (86%) of patients switched to rosuvastatin from a different statin are receiving the 5 or 10 mg doses (28% on 5 mg, 58% on 10 mg, 14% on 20 mg and 2% on 40 mg), and the majority (87%) of patients switched to atorvastatin from a different statin are receiving the 40 mg dose or lower (36% on 10 mg, 24% on 20 mg, 27% on 40 mg and 13% on 80 mg). Whether the safety and tolerability of maximum-dose statin monotherapy would have been similar to that of the ezetimibe/simvastatin
combination remains open to question and needs to be investigated in future studies. It should also be noted that the study did not assess the effects of combining ezetimibe with atorvastatin or rosuvastatin in patients not achieving target LDL-C goal with these drugs; further studies would be required to investigate the relative efficacy of this treatment approach.

Potential implications and unanswered questions

Our study shows that for high-risk patients who do not achieve desired targets for LDL-C with simvastatin 40 mg, a higher proportion will achieve LDL-C and total cholesterol targets with ezetimibe/simvastatin 10/40 mg than by switching to atorvastatin 40 mg or rosuvastatin 5–10 mg. A 2008 NICE Health Technology Assessment found that addition of ezetimibe to statin therapy was cost-effective compared with statin titration under specific scenarios, one of which was ezetimibe/simvastatin compared with switching to atorvastatin (14). Health economic studies are required to evaluate the budget implications for the NHS of routine prescribing of ezetimibe to achieve specified target LDL-C levels, given that NICE recommendations are not based solely on clinical efficacy, but also on cost-effectiveness and budget impact. Ultimately, data from clinical studies reporting cardiovascular events and mortality data associated with the addition of ezetimibe to statin treatment will be required to confirm the clinical benefits and safety profile of this therapeutic option.
AUTHOR CONTRIBUTIONS

TM is the guarantor; he was involved in discussions regarding the protocol, he was an investigator, he administrated the independent analysis and he was the Lead author of the writing committee. PH and RG were investigators and members of the writing committee. VA conducted the independent statistical analysis and was a member of the writing committee. RC and PR were involved in protocol design and clinical research operations and PR also contributed to the interpretation of the analysis. All authors had full access to all data and take responsibility for the integrity of the data and the accuracy of the data analysis, and approved the final version of the manuscript for publication.

ACKNOWLEDGEMENTS

The authors thank all of the investigators of the IN-PRACTICE study; Drs Mark Blagden, Charles Bundy, Tom Cahill, John Calvert, Johnathan Chapman, Glyn Chapman, Warwick Coulson, Frank Doig, Hugh Donnachie, Michael Duckworth, Alun George, Nigel Gough, David Haworth, Jerry Horn, Nick Jones, Neil Kerry, William Kleynhams, Chris Kyle, Teck Lee, Jennifer Litchfield, John Lovejoy, Richard Martin, Thomas Maxwell, Carol McKinnon, Michael Mutch, Juan Ochoa, Ian Orpen, Irina Pavel, Annette Pressman, Hilary Shaw, Hawys Thomas and Andrew Wijnberg.

The authors thank Dr Richard White (Oxford PharmaGenesis™ Ltd) for assistance in collating the comments of the writing committee on the initial draft manuscript (prepared by TM) and editing the final manuscript for submission. This role was funded by Merck Sharp & Dohme Ltd. Thanks are also due to Helen Tate (Sponsor...
Statistician) and Clare Mellon (Clinical Project Manager).

FUNDING
The study was supported by Merck Sharp & Dohme Ltd and Schering-Plough Ltd. The sponsor was involved in the study design, data collection and initial statistical analysis. The writing committee undertook an independent statistical analysis (VA) and were responsible for the interpretation of the data, the writing of the article and the decision to submit.
REFERENCES


ezetimibe/simvastatin 10/20 mg compared with rosvuastatin 10 mg in high-risk
hypercholesterolaemic patients inadequately controlled with prior statin monotherapy


### Table 1 Subject baseline and demographic characteristics (randomised population, $n = 786$)

<table>
<thead>
<tr>
<th></th>
<th>Ezetimibe/simvastatin 10/40 mg ($n = 261$)</th>
<th>Atorvastatin 40 mg ($n = 263$)</th>
<th>Rosuvastatin 5–10 mg ($n = 262$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years</strong></td>
<td>$64.7 \pm 8.7$</td>
<td>$64.2 \pm 8.4$</td>
<td>$63.9 \pm 8.6$</td>
</tr>
<tr>
<td>≥ 70 years, $n$ (%)</td>
<td>76 (29.1%)</td>
<td>76 (28.9%)</td>
<td>67 (25.6%)</td>
</tr>
<tr>
<td>**Male, $n$ (%)</td>
<td>160 (61.3%)</td>
<td>185 (70.3%)</td>
<td>178 (67.9%)</td>
</tr>
<tr>
<td>**Race, $n$ (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>254 (97.3%)</td>
<td>261 (99.2%)</td>
<td>257 (98.1%)</td>
</tr>
<tr>
<td>Asian</td>
<td>3 (1.1%)</td>
<td>0</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>Black</td>
<td>4 (1.5%)</td>
<td>0</td>
<td>2 (0.8%)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>2 (0.8%)</td>
<td>1 (0.4%)</td>
</tr>
<tr>
<td>Current smoker, $n$ (%)</td>
<td>44 (16.9%)</td>
<td>55 (20.9%)</td>
<td>47 (17.9%)</td>
</tr>
</tbody>
</table>
Cardiovascular disease

<table>
<thead>
<tr>
<th></th>
<th>Current CVD/diabetes, n (%)</th>
<th>High-risk CVD, n (%)</th>
<th>Mean 10-year CVD risk&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>138 (52.9%)</td>
<td>123 (47.1%)</td>
<td>131 (49.8%)</td>
</tr>
<tr>
<td></td>
<td>131 (49.8%)</td>
<td>131 (49.8%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>126 (48.1%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Diabetes

<table>
<thead>
<tr>
<th></th>
<th>Type 1, n (%)</th>
<th>Type 2, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 (0.8%)</td>
<td>40 (15.3%)</td>
</tr>
<tr>
<td></td>
<td>1 (0.4%)</td>
<td>26 (9.9%)</td>
</tr>
<tr>
<td></td>
<td>1 (0.4%)</td>
<td>32 (12.2%)</td>
</tr>
</tbody>
</table>

Fasting lipid levels, mmol/l

<table>
<thead>
<tr>
<th></th>
<th>LDL-C</th>
<th>HDL-C</th>
<th>Total cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.6 ± 0.4</td>
<td>1.4 ± 0.3</td>
<td>4.7 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>2.6 ± 0.4</td>
<td>1.4 ± 0.3</td>
<td>4.7 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>2.5 ± 0.4</td>
<td>1.4 ± 0.3</td>
<td>4.7 ± 0.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Triglycerides, median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.6 (0.7 to 3.8)</td>
</tr>
<tr>
<td></td>
<td>1.5 (0.7 to 4.0)</td>
</tr>
<tr>
<td></td>
<td>1.6 (0.7 to 4.3)</td>
</tr>
</tbody>
</table>

Values are mean ± SD unless otherwise stated.

<sup>a</sup>Excluding secondary prevention.

CVD, cardiovascular disease; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol.
Table 2 Summary of secondary and exploratory efficacy outcome measures (Full Analysis Set, n = 772)

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Ezetimibe/simvastatin 10/40 mg (n = 255)</th>
<th>Atorvastatin 40 mg (n = 259)</th>
<th>Rosuvastatin 5–10 mg (n = 258)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage change from baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL-C</td>
<td>-26.2 (–29.1 to –23.2)</td>
<td>-11.1 (–14.0 to –8.2)**</td>
<td>-3.0 (–5.9 to –0.1)**</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>-16.3 (–18.2 to –14.5)</td>
<td>-8.3 (–10.2 to –6.5)**</td>
<td>-2.5 (–4.4 to –0.7)**</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-9.5 (–12.5 to –6.7)</td>
<td>-8.1 (–11.8 to –2.9)</td>
<td>-4.3 (–7.0 to 0.0)</td>
</tr>
<tr>
<td>HDL-C</td>
<td>-1.4 (–2.9 to 0.0)</td>
<td>-2.3 (–3.7 to –0.9)</td>
<td>-0.1 (–1.5 to +1.3)</td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>-22.2 (–24.7 to –19.6)</td>
<td>-10.5 (–13.0 to –8.0)**</td>
<td>-3.1 (–5.6 to –0.6)**</td>
</tr>
<tr>
<td>Total cholesterol:HDL-C ratio</td>
<td>-14.4 (–16.4 to –12.4)</td>
<td>-5.5 (–7.5 to –3.4)**</td>
<td>-2.0 (–4.0 to 0.0)**</td>
</tr>
<tr>
<td>Apo A1</td>
<td>-1.6 (–3.1 to –0.2)</td>
<td>-4.5 (–5.9 to –3.1)*</td>
<td>+0.6 (–0.8 to +2.1)*</td>
</tr>
<tr>
<td>Apo B</td>
<td>-17.5 (–19.7 to –15.4)</td>
<td>-9.0 (–11.1 to –6.9)**</td>
<td>-3.2 (–5.3 to –1.1) **</td>
</tr>
<tr>
<td>Apo B:Apo A1 ratio</td>
<td>-15.4 (–17.8 to –12.9)</td>
<td>-3.8 (–6.2 to –1.4)**</td>
<td>-3.1 (–5.5 to –0.7) **</td>
</tr>
</tbody>
</table>

*p < 0.05, **p < 0.001 vs ezetimibe/simvastatin 10/40 mg.

Data are least-squares mean (95% CI) percentage change from baseline, except for triglycerides which are median percent change (ANOVA...
with treatment and strata as factors).

ANCOVA, analysis of variance; Apo, apolipoprotein; CI, confidence interval; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol.

*Predefined baseline LDL-C strata were ≥ 2.0 to < 2.5 mmol/l; ≥ 2.5 to < 3.0 mmol/l; and ≥ 3.0 to ≤ 4.2 mmol/l; the upper two strata were combined because there were too few patients in the highest stratum for analysis.

*Based on NICE guidance for treatment of patients with existing CVD and/or diabetes (analysis was *post hoc* because NICE treatment guidelines were published after the study was initiated).
Table 3. Tolerability of study treatments (All-Patients-as-Treated population, $n = 780$)

<table>
<thead>
<tr>
<th></th>
<th>Ezetimibe/simvastatin</th>
<th>Atorvastatin</th>
<th>Rosuvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10/40 mg ($n = 259$)</td>
<td>40 mg ($n = 260$)</td>
<td>5–10 mg ($n = 261$)</td>
</tr>
<tr>
<td>Any AE</td>
<td>89 (34.4)</td>
<td>93 (35.8)</td>
<td>103 (39.5)</td>
</tr>
<tr>
<td>Drug-related AE</td>
<td>23 (8.9)</td>
<td>22 (8.5)</td>
<td>27 (10.3)</td>
</tr>
<tr>
<td>AE leading to study discontinuation</td>
<td>7 (2.7)</td>
<td>5 (1.9)</td>
<td>9 (3.4)</td>
</tr>
<tr>
<td>Serious AE</td>
<td>4 (1.5)</td>
<td>2 (0.8)</td>
<td>5 (1.9)</td>
</tr>
<tr>
<td>Laboratory AE</td>
<td>5 (1.9)</td>
<td>3 (1.2)</td>
<td>1 (0.4)</td>
</tr>
</tbody>
</table>

Values are the number (%) of patients with at least one adverse experience (AE). AEs reported were those occurring or worsening after the first dose of double-blind study medication and up to 14 days following the last dose of study medication (or 30 days for serious AEs).
FIGURE LEGENDS

Figure 1. Patient flow through study
†Patients could have more than one reason for randomisation failure. ‡No further details recorded. Randomised population (demographic and baseline characteristics); APaT, All-Patients-as-Treated (APaT) population (safety analyses); Full Analysis Set (efficacy analyses). ALT/AST, alanine aminotransferase/aspartate aminotransferase; LDL-C, low-density-lipoprotein cholesterol; ULN, upper limit of normal.

Figure 2. Proportion of patients achieving low-density-lipoprotein cholesterol (LDL-C) < 2 mmol/l (< 77 mg/dl) and total cholesterol < 4 mmol/l (< 155 mg/dl) for ezetimibe/simvastatin 10/40 mg compared with atorvastatin 40 mg and with rosuvastatin 5–10 mg (Full Analysis Set).
Data are presented as adjusted proportions (95% confidence interval [CI]); ** indicates **p < 0.001 vs ezetimibe/simvastatin 10/40 mg in a logistic regression model with treatment and LDL-C stratum as factors.

Figure 3. Subgroup analysis of proportion of patients achieving low-density-lipoprotein cholesterol LDL-C treatment goals for ezetimibe/simvastatin 10/40 mg compared with atorvastatin 40 mg and with rosuvastatin 5–10 mg (Full Analysis Set)
Data are adjusted proportion (95% CI), using logistic regression analysis with treatment and strata as factors. †JBS-2 definition of secondary prevention for patients with existing CVD or CVD and diabetes; primary prevention for high-risk patients or patients with diabetes but no CVD. ‡NICE definition of secondary prevention for patients with existing CVD and/or diabetes; primary prevention for high-risk patients without diabetes. Analysis was post hoc.
because NICE treatment guidelines were published after the study was initiated. "Predefined baseline LDL-C strata were ≥ 2.0 to < 2.5 mmol/l; ≥ 2.5 to < 3.0 mmol/l; and ≥ 3.0 to ≤ 4.2 mmol/l; the upper two strata were combined because there were too few patients in the highest stratum for analysis.

CI, confidence interval; JBS, Joint British Societies; LDL-C, low-density-lipoprotein cholesterol; NICE, National Institute for Health and Clinical Excellence.

** indicates **p < 0.001 vs ezetimibe/simvastatin 10/40 mg in a logistic regression model with treatment and LDL-C stratum as factors.
Proportion of patients achieving LDL-C target

<table>
<thead>
<tr>
<th>LDL-C &lt; 2.0 mmol/l (JBS-2 criteria)</th>
<th>69.4 (62.9 to 75.2)</th>
<th>33.5 (27.6 to 39.9)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients (primary efficacy variable)</td>
<td>69.4 (62.9 to 75.2)</td>
<td>33.5 (27.6 to 39.9)**</td>
</tr>
<tr>
<td>Baseline LDL-C ≥ 2.5 to ≤ 4.2 mmol/l (JBS-2 secondary prevention only)</td>
<td>[n = 100]</td>
<td>[n = 109]</td>
</tr>
<tr>
<td>LDL-C &lt; 2.0 mmol/l (NICE criteria)</td>
<td>69.4 (61.1 to 76.7)</td>
<td>33.7 (26.1 to 42.2)**</td>
</tr>
<tr>
<td>Primary prevention only</td>
<td>[n = 155]</td>
<td>[n = 150]</td>
</tr>
<tr>
<td>NICE secondary prevention only</td>
<td>68.7 (59.5 to 76.7)</td>
<td>36.6 (28.1 to 46.0)**</td>
</tr>
<tr>
<td>[n = 131]</td>
<td>[n = 125]</td>
<td></td>
</tr>
<tr>
<td>NICE primary prevention only</td>
<td>70.5 (61.2 to 78.3)</td>
<td>30.9 (23.2 to 39.7)**</td>
</tr>
<tr>
<td>[n = 124]</td>
<td>[n = 134]</td>
<td></td>
</tr>
<tr>
<td>Baseline LDL-C 2.0 to &lt; 2.5 mmol/l</td>
<td>78.7 (71.0 to 84.8)</td>
<td>54.5 (46.0 to 62.7)**</td>
</tr>
<tr>
<td>[n = 136]</td>
<td>[n = 134]</td>
<td></td>
</tr>
<tr>
<td>Baseline LDL-C ≥ 2.5 to ≤ 4.2 mmol/l</td>
<td>54.6 (45.6 to 63.3)</td>
<td>16.8 (11.2 to 24.4)**</td>
</tr>
<tr>
<td>[n = 119]</td>
<td>[n = 125]</td>
<td></td>
</tr>
<tr>
<td>LDL-C ≤ 1.8 mmol/l</td>
<td>49.0 (42.4 to 55.6)</td>
<td>15.2 (11.3 to 20.2)**</td>
</tr>
<tr>
<td>LDL-C &lt; 2.5 mmol/l</td>
<td>92.1 (88.2 to 94.7)</td>
<td>74.1 (68.1 to 79.4)**</td>
</tr>
</tbody>
</table>